Magnitude and polarization of P53‐specific T‐helper immunity in connection to leukocyte infiltration of colorectal tumors

The tumor antigen p53 is mutated frequently and overexpressed in colorectal cancer. As a result, patients with this type of cancer commonly display p53‐specific T‐helper (Th) immunity. Examination of the cytokines produced by these Th‐cells showed that a majority of the proliferative p53‐specific T cell cultures produced none of the key cytokines (IFNγ, TNFα, IL‐4, IL‐5 or IL‐10), indicating that these p53‐specific Th‐responses are not polarized. In patients who exhibited p53‐specific reactivity against multiple p53‐epitopes, non‐polarized responses could be found side by side with polarized Th‐responses that produced INFγ or other cytokines such as IL‐10. Patients who exhibited p53‐specific IFNγ‐producing Th cell‐immunity before surgical excision of the tumor displayed higher numbers of tumor infiltrating intraepithelial leukocytes (p = 0.04) than patients lacking such responses, suggesting that the systemic presence of p53‐specific Th‐cells positively affects local tumor‐immunity. Our data concerning the polarization‐state of p53‐specific Th immunity in colorectal cancer patients support the use of vaccine formulations that induce strong Th1‐polarized p53‐specific immunity to ensure proper (re‐)programming of the anti‐tumor response. © 2003 Wiley‐Liss, Inc.

[1]  T. Oshikiri,et al.  CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. , 2003, Cancer research.

[2]  H. Putter,et al.  A basal membrane-like structure surrounding tumour nodules may prevent intraepithelial leucocyte infiltration in colorectal cancer , 2003, Cancer Immunology, Immunotherapy.

[3]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[4]  Antonio Lanzavecchia,et al.  Memory and flexibility of cytokine gene expression as separable properties of human TH1 and TH2 lymphocytes , 2003, Nature Immunology.

[5]  M. Nishimura,et al.  Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.

[6]  S. H. van der Burg,et al.  Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. , 2002, Cancer research.

[7]  S. H. van der Burg,et al.  Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes , 2002, Immunological reviews.

[8]  P. Loetscher,et al.  CXCR5(+) T cells: follicular homing takes center stage in T-helper-cell responses. , 2002, Trends in immunology.

[9]  S. H. van der Burg,et al.  Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  S. H. van der Burg,et al.  Long lasting p53‐specific T cell memory responses in the absence of anti‐p53 antibodies in patients with resected primary colorectal cancer , 2001, European journal of immunology.

[11]  N. Romani,et al.  Migration of dendritic cells into lymphatics-the Langerhans cell example: routes, regulation, and relevance. , 2001, International review of cytology.

[12]  S. H. van der Burg,et al.  Importance of CD4(+) T helper cell responses in tumor immunity. , 2000, Immunology letters.

[13]  R. Offringa,et al.  Cyclophosphamide enhances anti‐tumor effect of wild‐type p53‐specific CTL , 2000, International journal of cancer.

[14]  S. H. van der Burg,et al.  p53: A Potential Target Antigen for Immunotherapy of Cancer , 2000, Annals of the New York Academy of Sciences.

[15]  T. Soussi,et al.  p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.

[16]  H. Okamura,et al.  IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells , 2000 .

[17]  J. Drijfhout,et al.  Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. , 2000, Protein expression and purification.

[18]  S. H. van der Burg,et al.  Strategies for immunotherapy of cancer. , 2000, Advances in immunology.

[19]  Ishida,et al.  Dendritic cells transduced with wild‐type p53 gene elicit potent anti‐tumour immune responses , 1999, Clinical and experimental immunology.

[20]  R. Schreiber,et al.  CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ , 1999 .

[21]  C. Maliszewski,et al.  Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL , 1999, The Journal of experimental medicine.

[22]  P. Ricciardi-Castagnoli,et al.  Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo , 1999, Nature Medicine.

[23]  S. H. van der Burg,et al.  Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. , 1999, Journal of immunology.

[24]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[25]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[26]  G. Fleuren,et al.  Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[27]  J. Dayer,et al.  Human Th1 cells preferentially induce interleukin (IL)‐1β while Th2 cells induce IL‐1 receptor antagonist production upon cell/cell contact with monocytes , 1997, European journal of immunology.

[28]  E. Paoletti,et al.  p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Sakamoto,et al.  Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines , 1996, The Journal of experimental medicine.

[30]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[31]  H. Ploegh,et al.  HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. , 1990, International immunology.